- Human Biospecimens
- For Researchers
- For Biospecimen Contributors
- For Patients
August 21, 2015
The fact that the FDA has approved the first 3-D printed pill is a monumental achievement in the evolution of medicine. Not only could this forever impact the drug manufacturing industry, but also it has shown the world that the personalized medicine initiatives never before thought possible are becoming a reality. Today’s 3D printers allow production of infinitely different dosages – depending on the amount of active ingredient, or “chemical ink” that is released by the printer per pill.
While right now there is only one such drug that has been approved by the FDA, an epilepsy treatment called Spritam, the capability could enable a future in which all sorts of medications can be printed. And then, instead of static prescriptions, clinicians could provide individuals a dosage algorithm that is entirely tailored to them. For diseases such as epilepsy, in which patients often require very different medication potencies, this is indeed a game changer. True personalized medicine has arrived in the form of a pill. We are fascinated and wait in eager anticipation for the next breakthrough of this sort.
Below are links to two articles about the drug Spritam approved this month. Successes like this remind us that personalized medicine is not only here to stay, but here to change medicine as we know it.